Neumora
PublicNeumora is now publicly traded
The data on this page reflects Neumora's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 15, 2023
Last Round
Series B
Oct 11, 2022
Total Funding Raised
$862.1M
Company Overview
Neumora is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric disorders and neurodegenerative diseases through a unique approach to neuroscience.
Sector
Biotech
AI Layer
Infrastructure
Keywords
Neumora Comparables
Compare Neumora with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cerevance | 77% | |
| HMNC Brain Health | 72% | |
| Engrail Therapeutics | 70% |
For institutional investors. Book with your work email.
Neumora Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Sep 15, 2023 | ||||
| Series B | Oct 11, 2022 | ||||
| Series A | Oct 7, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neumora Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series B, Series A |
| Surveyor Capital | Series A |
| JP Morgan Securities | IPO |
| SoftBank Investment Advisers | Series A |
| DisruptAD | Series B |
| Guggenheim Securities | IPO |
| Waycross Ventures | Series A |
For institutional investors. Book with your work email.
Neumora Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.